HCP 2303
Alternative Names: HCP-2303Latest Information Update: 23 Apr 2024
At a glance
- Originator Hanmi Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 12 Apr 2024 Hanmi Pharmaceutical plans a phase I trial (In volunteers) in South Korea (PO) in May 2024 (NCT06357910)
- 05 Apr 2024 Preclinical trials in Unspecified in South Korea (PO) prior to April 2024
- 05 Apr 2024 Hanmi Pharmaceuticals plans a phase I pharmacokinetic trial (In volunteers) in South Korea (PO) (NCT06346184)